Vincerx Pharma Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023
March 14, 2023 16:35 ET
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
Vincerx Pharma to Participate at the SVB Securities Global Biopharma Conference
February 06, 2023 08:00 ET
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
Vincerx Pharma Announces FDA Safe to Proceed Letter for Investigational New Drug (IND) Application for its αVβ3 Small Molecule-Drug Conjugate (SMDC) VIP236
December 13, 2022 09:29 ET
|
Vincerx Pharma, Inc.
VIP236 is a first-in-class αVβ3 integrin binder SMDC with the potential to address a broad patient population across multiple solid tumor indications Preclinical studies with VIP236 demonstrated...
Vincerx Pharma Provides American Society of Hematology Annual Meeting 2022 Poster Highlights on Enitociclib in Multiple Tumor Types
December 12, 2022 16:05 ET
|
Vincerx Pharma, Inc.
In a multiple myeloma (MM) preclinical study, antitumor efficacy was observed with enitociclib as a monotherapy and in combination with several anti-MM agents Significant MYC downregulation was...
Vincerx Pharma Presents Preclinical Data on VIP943 in Acute Myeloid Leukemia Models at the 64th American Society of Hematology Annual Meeting 2022
December 11, 2022 10:05 ET
|
Vincerx Pharma, Inc.
Vincerx’s proprietary payload and linker technology and VIP943, a novel anti-CD123 antibody drug conjugate (ADC), demonstrated superiority with significant improved safety in non-human primates (NHP)...
Vincerx Pharma Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
November 10, 2022 16:05 ET
|
Vincerx Pharma, Inc.
Received Orphan Drug Designation for enitociclib; continue to focus on priority indications IND submission for first-in-class small molecule drug conjugate (SMDC) VIP236 expected by year-end IND...
Vincerx Pharma Announces Upcoming Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting 2022
November 03, 2022 09:05 ET
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
Vincerx Pharma Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
August 11, 2022 16:05 ET
|
Vincerx Pharma, Inc.
Continue to execute on priority indications for VIP152; recently issued the INN enitociclib IND submission for first-in-class small molecule drug conjugate (SMDC) VIP236 still expected in 2H2022 IND...
Vincerx Pharma Presents Preclinical and Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Lymphoma at the European Hematology Association 2022 Congress
June 10, 2022 08:00 ET
|
Vincerx Pharma, Inc.
Preclinical data demonstrate VIP152 as the most selective CDK9 inhibitor compared with other CDK9 inhibitors, with the most robust MYC mRNA downregulation Clinical data show improved selectivity,...
Vincerx Pharma Provides Key Strategic Update
June 06, 2022 16:05 ET
|
Vincerx Pharma, Inc.
Prioritizing Phase 1b VIP152 studies to focus on double-hit DLBCL and CLL Continuing to advance next-generation modular bioconjugation platform; IND filings for VIP236 in 2H22 and for VIP943 in...